{"id":"insulin-aspart-6-day-reservoir-in-use","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201496","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin aspart is a recombinant human insulin analog with a rapid onset and short duration of action. It mimics the body's natural insulin response to meals by binding to insulin receptors on muscle and fat cells, promoting glucose uptake and storage while suppressing hepatic glucose production. The 6-day reservoir formulation extends the duration of action compared to standard insulin aspart, allowing for less frequent dosing.","oneSentence":"Insulin aspart is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:17.769Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT01109316","phase":"PHASE3","title":"Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-04","conditions":"Diabetes Mellitus, Type 1","enrollment":132},{"nctId":"NCT01134107","phase":"PHASE3","title":"Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-11","conditions":"Diabetes Mellitus, Type 1","enrollment":133}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Insulin aspart 6 day reservoir in-use","genericName":"Insulin aspart 6 day reservoir in-use","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin aspart is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}